|By Marketwired .||
|April 17, 2014 10:24 AM EDT||
TORONTO, ONTARIO -- (Marketwired) -- 04/17/14 -- Arch Biopartners Inc ("Arch" or the "Company") (CNSX: ACH)(OTCBB: FOIFF) announced today the board has appointed Claude Allary as an interim director.
Mr. Allary currently is in Paris working as independent consultant and executive coach in life sciences. He was most recently a managing partner of Bionest, a pharmaceutical consulting firm with offices in Paris and New York that he co-founded in 2003. Prior to Bionest, Mr Allary accumulated over 20 years of experience within the pharmaceutical industry, successively with Rhone-Poulenc Sante (now Sanofi), Parke-Davis (now Pfizer) and Glaxo. He also spent 7 years with Arthur D. Little in London, Brussels and Paris, followed by 4 years with ISO Health Care Group. He has been an advisor to Arch since 2012.
"We are pleased to have Mr. Allary join the board of Arch. His wealth of knowledge and experience will benefit the Company as it builds out its team and pursues commercial opportunities" said Richard Muruve, CEO and director of Arch.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies. The Company's lead technology is in the area of targeting brain tumor initiating cells for the purpose of developing new imaging, diagnostic and therapeutic treatments for malignant glioma. The Company's website address is: www.archbiopartners.com.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.
Mar. 4, 2015 03:30 AM EST Reads: 2,684
Mar. 4, 2015 02:45 AM EST Reads: 3,801
Mar. 4, 2015 02:30 AM EST Reads: 1,152
Mar. 4, 2015 02:00 AM EST Reads: 3,123
Mar. 4, 2015 01:30 AM EST Reads: 3,506
Mar. 4, 2015 01:00 AM EST Reads: 4,379
Mar. 4, 2015 12:30 AM EST Reads: 3,532
Mar. 4, 2015 12:00 AM EST Reads: 3,086
Mar. 3, 2015 11:15 PM EST Reads: 740
Mar. 3, 2015 10:00 PM EST Reads: 1,055
Mar. 3, 2015 09:15 PM EST Reads: 859
Mar. 3, 2015 07:30 PM EST Reads: 945
Mar. 3, 2015 06:30 PM EST Reads: 705
Mar. 3, 2015 05:30 PM EST Reads: 619
VictorOps is making on-call suck less with the only collaborative alert management platform on the market. With easy on-call scheduling management, a real-time incident timeline that gives you contextual relevance around your alerts and powerful reporting features that make post-mortems more effective, VictorOps helps your IT/DevOps team solve problems faster.
Mar. 3, 2015 05:00 PM EST Reads: 1,357